9 Key Takeaways
-
1
Study shows PDE-5 inhibitors may lower gastric cancer risk in older men.
-
2
Cohort included nearly 795,000 patients.
-
3
Users had a lower odds ratio of gastric cancer (OR 0.7).
-
4
H. pylori infection elevated risks (OR
-
5
33).
-
6
Further studies are recommended to explore anti-tumor effects.
-
7
Colorectal cancer rates were also reduced (OR 0.68).
-
8
Subgroup analysis was conducted for H. pylori-infected patients.
-
9
No relevant financial relationships reported by the research team.
A recent retrospective cohort study presented at the American College of Gastroenterology 2025 Annual Scientific Meeting reveals that adult males aged 60 and older who take PDE-5 inhibitors such as sildenafil, tadalafil, or vardenafil exhibit significantly lower rates of gastric and colorectal cancers. The analysis encompassed nearly 795,000 patients and indicated reduced gastric cancer rates (OR 0.7) in users, although those with Helicobacter pylori infections showed a notable increase in risk (OR 2.33). The study suggests a need for further prospective research to explore these findings.
Listen Tab content
